Table 3.

ECI

ECI*	All treated patients (N = 99), n (%)
	All grades	Grade ≥3
Cardiac events	20 (20)†	4 (4)
Atrial fibrillation	5 (5)‡	2 (2)
Ventricular tachyarrhythmias	0	0
Anemia	8 (8)	2 (2)
Leukopenia	9 (9)	9 (9)
Neutropenia	9 (9)	9 (9)
Other leukopenia	1 (1)	1 (1)
Thrombocytopenia	3 (3)	1 (1)
Hemorrhage §	65 (66)	3 (3)
Major hemorrhage‖	4 (4)	3 (3)
Hepatotoxicity	4 (4)	2 (2)
Hypertension	22 (22)	11 (11)
Infections¶ , #	83 (84)	15 (15)
Interstitial lung disease/pneumonitis	1 (1)	0
Second primary malignancies	26 (26)	5 (5)
Second primary malignancies, excluding nonmelanoma skin	11 (11)	5 (5)
Tumor lysis syndrome	0	0

ECIs, events of clinical interest; UTI, urinary tract infection.

^*ECIs were based on combined AE terms for infections, bleeding events, hypertension, and second primary malignancies, excluding nonmelanoma skin and on a single AE term for atrial fibrillation.

^†Other cardiac events occurring in >1 patient included tachycardia (n = 8; all grade 1), sinus tachycardia (n = 3; all grade 1), palpitations (n = 3 [grade 1, n = 2; grade 2, n = 1]), and angina pectoris (n = 2; both grade 2).

^‡Age range: 68 to 79 y.

^§Most common bleeding events (all grade, ≥15%) were contusion (42%), petechiae (18%), and ecchymosis (16%).

^‖Includes 1 grade 1 AE (retinal hemorrhage) and 3 grade 3 AEs (hematuria, traumatic intracranial hemorrhage, and upper gastrointestinal hemorrhage).

^¶Most common infections (all grade, ≥15%) were upper respiratory tract infections (44%) and sinusitis (21%); among patients with opportunistic infections, grade 2 fungal infection, grade 2 coccidioidomycosis, and grade 2 herpes zoster were reported in 1 patient each, and 1 patient experienced both grade 3 perineal infection fungal and grade 3 herpes zoster.

^#Acalabrutinib dosing was delayed in 10 patients because of infection AEs; 2 patients discontinued acalabrutinib because of grade 3 UTI and grade 4 sepsis.